Simple. Stable. Easy.
Windgap Medical designs, develops, and manufactures life-changing drug delivery devices for essential medications.
In partnership with forward-thinking, patient-centered organizations, our assertive development pipeline is growing across several treatment areas.
Featured Products
EPINEPHRINE AUTOINJECTOR: ANDI® PLATFORM
Currently in pilot production. Out-licensed to ALK-Abelló
Our thermally stable drug delivery platform will automate rehydration and administration with twice the shelf life and half the size of current anaphylaxis treatments.
SULFANEGEN AUTOINJECTOR
Funded by a grant from the National Institutes of Health, Windgap Medical has partnered with the University of Minnesota to develop an emergency treatment autoinjector for first responders and fire victims exposed to cyanide through smoke inhalation.
GLUCAGON AUTOINJECTOR
Opportunity in development: Currently seeking partnerships
Windgap’s autoinjector offers an approved dosage that can be performed accurately, easily, and instantly by anyone—even a patient in the early stages of hypoglycemic crisis.
Capabilities
Accelerating the development and impact of difficult-to-stabilize drugs.
Taking a powdered product from clinical development all the way to commercial production can be made faster and at a lower cost than redeveloping a stable liquid formulation mid-way through R&D.
STABILIZE HEAT- AND TIME-SENSITIVE LIQUIDS
Liquid medications typically have a poor stability profile. Our wet-dry autoinjectors contain drugs in their most stable state, offering unprecedented temperature resilience, shelf life, and patient compliance.
THERAPEUTIC AREAS
- Anaphylaxis (Epinephrine)
- Epilepsy
- Rheumatoid Arthritis
- Pain management
- Vaccinations (supply chain)
Over 32 million Americans have food allergies—including 5.6 million children.
SIMPLIFY AWKWARD DELIVERY SYSTEMS
Lyophilized drugs can require multiple complicated steps—and take over two minutes—to administer a life-saving dose of rescue glucagon. Our self-administered ANDI® platform does it in two steps—and in seconds.
THERAPEUTIC AREAS
- Cyanide exposure (smoke inhalation)
- Hypoglycemia
- Hemophilia
- Migraine headaches
- Pituitary disease
Over 500,000 doses of cyanide anecdotes are administered annually.
mix EXTENDED RELEASE formulations
Current long-acting injectables require complicated preparation steps, often with dosing and degradation issues. Our in-device mixing mechanisms automate and control this process to protect the medication, the patient, and the outcome.
THERAPEUTIC AREAS
- Cancer
- Diabetes
- Opioid addiction
- Anti-psychotics
- Family planning
16.3 million Americans suffer from opioid addiction
We are currently seeking partners to develop the above devices and injection therapies.
Pipeline
| Product | Partner | Therapeutic Area | Feasibility | PIND | Filed | Approved |
|---|---|---|---|---|---|---|
| ANDIPEN® | ALK-Abello | Anaphylaxis / Allergies |  | | ||
| SULFANEGEN | NIH | Cyanide Exposure | | | ||
| GLUCAGON | Seeking partnership | Diabetes / Hypoglycemia | | |||
| WG-2024 | Oncology | |||||
| WG-2025 | CNS | |||||
| WG-2027 | Opioid Addiction / Overdose Emergencies |